MRD-positive AML Clinical Study
- Status
- RECRUITING
- Phase
- NA
Clinical Trials Related to Cytarabine
Related studies linked through entity extraction aliases.
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
- Status
- RECRUITING
- Phase
- PHASE2
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE3
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
- Status
- RECRUITING
- Phase
- PHASE2
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
- Status
- RECRUITING
- Phase
- PHASE2
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
- Status
- RECRUITING
- Phase
- PHASE2
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
- Status
- RECRUITING
- Phase
- PHASE3
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy
- Status
- RECRUITING
- Phase
- NA
Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML
- Status
- RECRUITING
- Phase
- PHASE2